FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W658207740> ?p ?o ?g. }

• W658207740 abstract "In the present study the mechanisms leading to acquired chemoresistance, as well as newtreatment strategies implying the prevention evading of tumor cells were addressed.Resistance formation is one of the major hurdles in cancer therapy. Metronomic antiangiogenictreatment of xenografted prostate cancer tumors in mice with cyclophosphamide(CPA) results in the appearance of resistant tumors. To investigate the complex molecularchanges occurring during resistance formation, a comprehensive gene expression analysis ofthe resistant tumors in vivo was performed. A multitude of differentially expressed genes,e.g. PAS domain containing protein 1 (PASD1), annexin A3 (ANXA3), neurotensin (NTS) orplasminogen activator tissue (PLAT), were observed, when comparing resistant to in vivopassaged tumor samples. Moreover, tumor cells from in vivo and in vitro conditions showeda significant difference in target gene expression. For clarification of the mechanisms leading to the survival of tumor cells during maintained anti-angiogenic CPA therapy thedifferentially expressed genes were assigned to functional pathways like: axon guidance, steroid biosynthesis and complement and coagulation cascades. As blood flow might play a crucial role during maintained anti-angiogenic therapy, further analysis was focused on the genes grouped in complement and coagulation cascades. pregulation of anti-coagulatory ANXA3 and PLAT and downregulation of SERPIN A1 and other SERPIN-family members was shown by qPCR analysis. In contrast coagulation factor F3 was upregulated, accompanied by the expression of an altered gene product. Taken together, a potential role of anticoagulation as a resistance mechanism for anti-angiogenic CPA therapy could be described.Furthermore, the role of archazolid, a novel myxobacterial V-ATPase inhibitor in cancertreatment and in particular its action on the secreted cellular proteome was evaluated. Asextracellular protein secretion may have an impact on invasive properties of tumor cells, thechanges of the secretome profile of highly migratory urinary bladder carcinoma cells uponarchazolid treatment were analyzed. An induced secretion of prometastatic lysosomalproteins such as the cathepsin family was observed. Interestingly, intracellular cathepsin Bactivity however strongly decreases and mature cathepsin B protein diminishes. It could beshown that archazolid inhibits the mannose-6-phosphate receptor mediated trafficking ofprocathepsin B from the trans-Golgi network to prelysosomal compartments, leading to animpaired cathepsin B maturation process. This results in an unnatural secretion of the inactive proenzyme and a dramatic decrease in intracellular cathepsin B activity.Importantly, also in vivo an archazolid induced reduction of cathepsin B activity was provenand archazolid treatment resulted in a reduced formation of distant metastases in the lungs.In summary these results indicate that archazolid in addition to its known anti-migratoryproperties might exert an anti-metastatic effect by reducing the activity of pro metastaticproteases like cathepsin B." @default.
• W658207740 created "2016-06-24" @default.
• W658207740 creator A5086340220 @default.
• W658207740 date "2013-06-27" @default.
• W658207740 modified "2023-09-27" @default.
• W658207740 title "Mechanism of cancer evading metronomic chemotherapy and action of Archazolid as an anti-metastatic drug" @default.
• W658207740 hasPublicationYear "2013" @default.
• W658207740 type Work @default.
• W658207740 sameAs 658207740 @default.
• W658207740 citedByCount "0" @default.
• W658207740 crossrefType "journal-article" @default.
• W658207740 hasAuthorship W658207740A5086340220 @default.
• W658207740 hasConcept C104317684 @default.
• W658207740 hasConcept C111599444 @default.
• W658207740 hasConcept C111684460 @default.
• W658207740 hasConcept C121608353 @default.
• W658207740 hasConcept C126322002 @default.
• W658207740 hasConcept C127561419 @default.
• W658207740 hasConcept C134018914 @default.
• W658207740 hasConcept C150903083 @default.
• W658207740 hasConcept C159654299 @default.
• W658207740 hasConcept C203014093 @default.
• W658207740 hasConcept C207001950 @default.
• W658207740 hasConcept C2779679481 @default.
• W658207740 hasConcept C2780394083 @default.
• W658207740 hasConcept C502942594 @default.
• W658207740 hasConcept C55493867 @default.
• W658207740 hasConcept C56219504 @default.
• W658207740 hasConcept C71924100 @default.
• W658207740 hasConcept C86803240 @default.
• W658207740 hasConceptScore W658207740C104317684 @default.
• W658207740 hasConceptScore W658207740C111599444 @default.
• W658207740 hasConceptScore W658207740C111684460 @default.
• W658207740 hasConceptScore W658207740C121608353 @default.
• W658207740 hasConceptScore W658207740C126322002 @default.
• W658207740 hasConceptScore W658207740C127561419 @default.
• W658207740 hasConceptScore W658207740C134018914 @default.
• W658207740 hasConceptScore W658207740C150903083 @default.
• W658207740 hasConceptScore W658207740C159654299 @default.
• W658207740 hasConceptScore W658207740C203014093 @default.
• W658207740 hasConceptScore W658207740C207001950 @default.
• W658207740 hasConceptScore W658207740C2779679481 @default.
• W658207740 hasConceptScore W658207740C2780394083 @default.
• W658207740 hasConceptScore W658207740C502942594 @default.
• W658207740 hasConceptScore W658207740C55493867 @default.
• W658207740 hasConceptScore W658207740C56219504 @default.
• W658207740 hasConceptScore W658207740C71924100 @default.
• W658207740 hasConceptScore W658207740C86803240 @default.
• W658207740 hasLocation W6582077401 @default.
• W658207740 hasOpenAccess W658207740 @default.
• W658207740 hasPrimaryLocation W6582077401 @default.
• W658207740 hasRelatedWork W1496895704 @default.
• W658207740 hasRelatedWork W1983288410 @default.
• W658207740 hasRelatedWork W2005025018 @default.
• W658207740 hasRelatedWork W2022137114 @default.
• W658207740 hasRelatedWork W2062230950 @default.
• W658207740 hasRelatedWork W2098644216 @default.
• W658207740 hasRelatedWork W2110227636 @default.
• W658207740 hasRelatedWork W2132163449 @default.
• W658207740 hasRelatedWork W2132954482 @default.
• W658207740 hasRelatedWork W2178243564 @default.
• W658207740 hasRelatedWork W2215100157 @default.
• W658207740 hasRelatedWork W2243523388 @default.
• W658207740 hasRelatedWork W2326548029 @default.
• W658207740 hasRelatedWork W2443143122 @default.
• W658207740 hasRelatedWork W2626111643 @default.
• W658207740 hasRelatedWork W2889373312 @default.
• W658207740 hasRelatedWork W2949035086 @default.
• W658207740 hasRelatedWork W2949650109 @default.
• W658207740 hasRelatedWork W3042654301 @default.
• W658207740 hasRelatedWork W3147530535 @default.
• W658207740 isParatext "false" @default.
• W658207740 isRetracted "false" @default.
• W658207740 magId "658207740" @default.
• W658207740 workType "article" @default.